Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
- PMID: 33719003
- PMCID: PMC8118193
- DOI: 10.1007/s11912-021-01029-7
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Abstract
Purpose of review: The purpose of our review is to explore global epidemiologic trends of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Specifically, we sought to examine whether there are differences in incidence, prevalence, distribution (by primary tumor site, tumor grade, tumor stage at presentation), and overall survival of GEP NETs between different regions of the world.
Recent findings: GEP NET incidence rates are rising steadily in North America, Asia, and Europe, though this rise appears to be most profound in North America. The distribution of GEP NETs differs regionally as in North America small intestinal and rectal NETs are most prevalent, in Asia rectal and pancreatic NETs are most prevalent, and in Europe small intestinal and pancreatic NETs are most prevalent. Overall survival for patients with GEP NETs appears to be improving with time. Some of the global increase in GEP NET incidence can be explained by increased health care utilization. This factor alone, however, does not explain the rise completely. Population-based studies utilizing uniform data collection instruments and a standard pathologic grading system are needed to identify other factors which may be contributing to this phenomenon.
Keywords: Gastroenteropancreatic neuroendocrine neoplasms; Global epidemiology; Incidence; Neuroendocrine carcinoma; Neuroendocrine tumors; Prevalence.
Similar articles
-
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.Mil Med Res. 2024 Jun 4;11(1):35. doi: 10.1186/s40779-024-00535-6. Mil Med Res. 2024. PMID: 38835066 Free PMC article. Review.
-
Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.Endocr Relat Cancer. 2014 May 6;21(3):R153-63. doi: 10.1530/ERC-13-0125. Print 2014 Jun. Endocr Relat Cancer. 2014. PMID: 24322304 Review.
-
Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.Cancer Med. 2020 Dec;9(24):9454-9461. doi: 10.1002/cam4.3524. Epub 2020 Oct 20. Cancer Med. 2020. PMID: 33078908 Free PMC article.
-
Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.Asia Pac J Clin Oncol. 2016 Sep;12(3):284-8. doi: 10.1111/ajco.12498. Epub 2016 May 12. Asia Pac J Clin Oncol. 2016. PMID: 27170574
-
Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.Clin Gastroenterol Hepatol. 2019 Oct;17(11):2212-2217.e1. doi: 10.1016/j.cgh.2018.12.017. Epub 2018 Dec 20. Clin Gastroenterol Hepatol. 2019. PMID: 30580091
Cited by
-
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.Mil Med Res. 2024 Jun 4;11(1):35. doi: 10.1186/s40779-024-00535-6. Mil Med Res. 2024. PMID: 38835066 Free PMC article. Review.
-
Identifying patients with undiagnosed small intestinal neuroendocrine tumours in primary care using statistical and machine learning: model development and validation study.Br J Cancer. 2024 Jun 3. doi: 10.1038/s41416-024-02736-1. Online ahead of print. Br J Cancer. 2024. PMID: 38831012
-
Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.J Gastrointest Cancer. 2024 May 30. doi: 10.1007/s12029-024-01072-0. Online ahead of print. J Gastrointest Cancer. 2024. PMID: 38814411
-
CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.Cancers (Basel). 2024 May 8;16(10):1799. doi: 10.3390/cancers16101799. Cancers (Basel). 2024. PMID: 38791878 Free PMC article. Review.
-
Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study.BMC Public Health. 2024 May 24;24(1):1396. doi: 10.1186/s12889-024-18845-8. BMC Public Health. 2024. PMID: 38789981 Free PMC article.
References
-
- Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares J, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. - PubMed
-
- Sorbye H, Strosberg J, Baudin E, Klimstra D, Yao J. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–23. - PubMed
-
- Chauhan A, Kohn E, Del Rivero J. Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence. JAMA Oncol. 2020;6(1):21–2 - PMC - PubMed
-
An important recent publication highlighting the disease prevalence of gastrointestinal NETs and further all NETs in the United States. This publication suggests the public health importance of NETs.
-
- Cives M, Strosberg J. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471–87. - PubMed
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials